摘要
[目的]分析应用益生菌联合序贯疗法用于幽门螺杆菌相关性慢性萎缩性胃炎治疗的效果以及安全性。[方法]选取2008年1月1日～2014年3月31日在我院进行治疗的幽门螺杆菌相关性慢性萎缩性胃炎患者300例,随机选出200例患者将其平均分成2组,对照组采用序贯疗法,治疗组采用益生菌联合序贯疗法,分别比较2组的幽门螺杆菌相关性慢性萎缩性胃炎根除率、临床疗效以及用药不良反应发生率。[结果]治疗组的总有效率（90.00%）高于对照组（83.00%）,差异无统计学意义;治疗组的幽门螺杆菌根除率（98.00%）显著高于对照组（73.00%）;治疗组的不良反应发生率（43.00%）显著低于对照组（68.00%）,差异有统计学意义（P〈0.05）。[结论]益生菌联合序贯疗法治疗幽门螺杆菌相关性慢性萎缩性胃炎具有一定优势,提高了用药的安全性,保证患者治疗的有效性。
[Objective]To analyze efficacy and safety of probiotics combined sequential therapy in the treatment of Helicobacter pylori related chronic atrophic gastritis.[Methods]Two hundred cases of Helicobacter pylori-associated chronic atrophic gastritis patients in our hospital from January 1,2008 to March31,2014 were randomly divided into two groups：control group treated with sequential therapy and treatment group with probiotics combined sequential therapy.The two groups were compared in eradication rate of Helicobacter pylori-associated chronic atrophic gastritis,clinical efficacy and incidence of adverse drug reactions.[Results]The total efficiency of the treatment group（90.00%）was higher than the control group（83.00%）,while the difference was not statistically significant.Eradication rate of Helicobacter pylori in the treatment group（98.00%）was significantly higher than the control group（73.00%）.Incidence of adverse reactions in the treatment group（43.00%）was significantly lower than the control group（68.00%）,and the difference was statistically significant（P〈0.05）.[Conclusion]Probiotics combined sequential therapy for Helicobacter pylori related chronic atrophic gastritis had certain advantages with the improvement of medication safety and ensurement of the effectiveness.
出处
《中国中西医结合消化杂志》
CAS
2015年第2期88-90,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
基金
全国统计科学研究项目(No:2014LY110)
关键词
慢性萎缩性胃炎
幽门螺杆菌
益生菌联合序贯疗法
chronic atrophic gastritis
Helicobacter pylori
probiotics combined sequential therapy
